ENZO BIOCHEM BLAMES LOSS ON LAB CONSOLIDATIONEnzo Biochem Inc. (ASE:ENZ) of New York said its 1991 first-quarter loss of $952,000 reflected the costs of consolidatingEnzoLabs Inc. into a new facility in Farmingdale, N.Y., a movethat was aimed at leading to future cost reductions.

First quarter ended Oct. 31

(Figures in thousands except per-share data.)

1991 1990 Percent change

Revenues 5,481 5,535 negl.Net income (loss) (952) (770) -24Net income per share (loss) (.08) (.07) -14Outstanding shares 11,359 11,359 n.a.

SURVIVAL TECH HELPED BY DEFENSE CONTRACT

Survival Technology Inc. (NASDAQ:SURV) of Bethesda, Md., saida $252,000 profit in the first quarter marked the company'sfourth consecutive profitable quarter. The improvement waspartly attributed to a Defense Department request for theproduction of Survival Tech's Mark I Antidote Kits fordeployment to troops serving in the Middle East. In addition,approval of Syntex Laboratories' drug Toradol generated $2.6million in sales of Survival's cartridge syringe system.

First quarter ended Oct. 31

(Figures in thousands except per-share data.)

1991 1990 Percent change

Revenues 9,600 2,900 +231Net income (loss) 252 (1,493) n.a.Net income per share (loss) .09 (.53) n.a.Outstanding shares 2,922 2,841 +3

INTERNEURON REPORTS LOSS TRIPLED IN SIZE

Interneuron Pharmaceuticals Inc. (NASDAQ:IPIC) of Lexington,Mass., said its $2.4 million loss for the year ended Sept. 30reflected substantial increase in research and development inthe areas of drug discovery and product development.

Year ended Sept. 30

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues 534 17 +3,041Net income (loss) (2,367) (598) -296Net income per share (loss) (.17) (.06) -183Outstanding shares 13,651 9,438 +45

LIDAK SAYS BIGGER LOSS TIED TO GROWTH

Lidak Pharmaceuticals (NASDAQ:LDAKU) of La Jolla, Calif., saidits sharply larger 1990 loss reflects a one-time charge toresearch and development expenses of about $818,000 andcosts associated with expanding facilities, hiring staff andinitiating pre-clinical toxicological studies.

Year ended Sept. 30

(Figures in thousands of dollars except per-share data.)

1990 1989 Percent change

Revenues 372 4 +9200Net income (loss) (2,319) (410) -466Net income per share (loss) (.61) (.27) -126Outstanding shares 3,813 1,538 +148

PHARMAKINETICS POSTS BIG LOSS

PharmaKinetics Laboratories Inc. (NASDAQ:PKLBQ) of Baltimoreattributed a sharply deeper first-quarter loss to a decline theshutdown of its clinical trials division last August andunderperformance by the biopharmaceutics division. Thecompany filed for Chap. 11 bankruptcy in November.

First quarter ended Sept. 30

(Figures in thousands of dollars except per-share data.)

1991 1990 Percent change

Revenues 4,467 6,664 -33Net income (loss) (769) (393) -96Net income per share (loss) (.08) (.04) -100Outstanding shares 10,085 9,197 +10

(c) 1997 American Health Consultants. All rights reserved.

No Comments